BlackRock discloses stake in Mural Oncology plc

LONDON - Investment management firm BlackRock (NYSE:BLK), Inc. has disclosed its shareholding and short positions in Mural Oncology plc, a company currently involved in a takeover situation governed by the rules of the Irish Takeover Panel. As of April 30, 2025, BlackRock holds a total interest of 1.40% in Mural Oncology, which translates to 242,291 ordinary shares. Additionally, BlackRock has a short position representing 0.41% of the company, amounting to 71,756 shares.

The disclosure is a regulatory requirement under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, which mandates that any person with an interest in relevant securities representing 1% or more must report their position. This rule ensures transparency during takeover bids and is crucial for maintaining fair market practices.

BlackRock’s report also mentioned dealings in Mural Oncology’s shares, including the stock on loan transactions. The firm loaned out 32,200 shares and subsequently saw the return of 40,800 shares. However, there were no transactions reported in cash-settled or stock-settled derivatives.

The disclosure did not indicate any indemnity or dealing arrangements that could serve as an inducement to deal or refrain from dealing in the securities of Mural Oncology. Furthermore, there were no attachments or supplemental forms provided with the disclosure.

The information contained in this article is based on a press release statement and is intended to provide shareholders and the investing public with relevant facts regarding BlackRock’s holdings and positions in Mural Oncology plc. It is important for investors to be aware of significant shareholdings and short positions in companies that are subjects of takeover rumors or confirmed bids, as these can have implications for market perceptions and the stock’s performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.